Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's acquirer interested in breast, pancreatic, and GI CA

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 26, 2023 12:45pm

121 Views

Post# 35465975

RE:RE:ONCY's acquirer interested in breast, pancreatic, and GI CA

"BRACELET-1's data greatly enhance our pipeline's value proposition, bringing our breast cancer program to pivotal trial-readiness and confirming pelareorep's potential to address large markets by synergistically combining with other anti-cancer agents.

Looking ahead, we believe our data in breast cancer, together with the second registration opportunity offered by our pancreatic cancer program, leave us well-positioned as we continue to execute our business development efforts." - Andrew de Guttadauro

Big Pharma's 'eager' interest eminates from ASCO's invitation to have the Bracelet-1 Phase 2 results presented at an oral presentation during their annual meeting and ONCY's KOL meeting during ASCO which has Dr. Martine J. Piccart on the panel.

Martine J. Piccart, M.D., Ph.D., is an Honorary Professor of Oncology at the Universit Libre de Bruxelles (ULB), Belgium, and Scientific Director at the Institut Jules Bordet.

She is a co-founder and chair of the Breast International Group (BIG), uniting more than 60 academic research groups from around the world, running over 30 trials, and developing numerous research programs. AURORA, a study to better understand metastatic breast cancer, is the most ambitious of these.

Dr. Piccart is the past president of the European Organisation for Research and Treatment of Cancer (EORTC), the European Society for Medical Oncology (ESMO), and the European Cancer Organisation (ECCO). She served on the ASCO and American Association for Cancer Research (AACR) Boards. Author or co-author of more than 540 peer-reviewed publications, she has received numerous prestigious awards, including the Jill Rose Award, the William L. McGuire Award, the Umberto Veronesi Award for the Future Fight against Cancer, the 2013 David A. Karnofsky Memorial Award, the Leopold Griffuel Award and the Bob Pinedo Award in 2018.

https://stockhouse.com/news/press-releases/2023/05/26/oncolytics-biotech-xae-to-host-key-opinion-leader-webinar-on-data-from-the

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024